UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1844) 1844
science & technology (1736) 1736
life sciences & biomedicine (1702) 1702
diabetes mellitus, type 2 - drug therapy (1443) 1443
dipeptidyl-peptidase iv inhibitors - therapeutic use (1153) 1153
male (937) 937
type 2 diabetes (860) 860
hypoglycemic agents - therapeutic use (854) 854
female (811) 811
dipeptidyl-peptidase iv inhibitors - adverse effects (788) 788
endocrinology & metabolism (736) 736
middle aged (705) 705
diabetes (704) 704
hypoglycemic agents - adverse effects (578) 578
aged (577) 577
treatment outcome (504) 504
pharmacology & pharmacy (447) 447
diabetes mellitus, type 2 - blood (423) 423
adult (398) 398
animals (394) 394
dipeptidyl-peptidase iv inhibitors - administration & dosage (385) 385
adamantane - analogs & derivatives (380) 380
hypoglycemic agents (369) 369
glucose (345) 345
dipeptidyl-peptidase iv inhibitors - pharmacology (342) 342
drug therapy, combination (339) 339
hypoglycemic agents - administration & dosage (326) 326
risk factors (319) 319
diabetes mellitus (318) 318
blood glucose - drug effects (311) 311
blood glucose - metabolism (295) 295
care and treatment (283) 283
metformin - therapeutic use (266) 266
sitagliptin phosphate (260) 260
type 2 diabetes mellitus (257) 257
drug therapy (255) 255
analysis (250) 250
adamantane - therapeutic use (249) 249
double-blind method (247) 247
insulin (247) 247
diabetes mellitus, type 2 - complications (246) 246
glycated hemoglobin a - metabolism (244) 244
diabetes therapy (242) 242
general & internal medicine (240) 240
dipeptidyl peptidase 4 - metabolism (227) 227
medicine, general & internal (226) 226
sitagliptin (222) 222
clinical trials (221) 221
internal medicine (219) 219
research (210) 210
hypoglycemic agents - pharmacology (205) 205
adamantane - adverse effects (204) 204
peptidase (202) 202
cardiovascular system & cardiology (195) 195
dextrose (195) 195
hypoglycemia - chemically induced (195) 195
abridged index medicus (187) 187
vildagliptin (180) 180
glucagon (176) 176
sulfonylurea compounds - therapeutic use (174) 174
metformin (173) 173
triazoles - therapeutic use (170) 170
pyrazines - therapeutic use (169) 169
medicine & public health (168) 168
linagliptin (167) 167
randomized controlled trials as topic (166) 166
peptides (162) 162
cardiac & cardiovascular systems (161) 161
dpp-4 inhibitor (161) 161
hypoglycemia (161) 161
dosage and administration (160) 160
diabetes mellitus, type 2 - metabolism (157) 157
pyrrolidines - therapeutic use (156) 156
time factors (156) 156
dipeptidyl-peptidase iv inhibitors (154) 154
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (154) 154
nitriles - therapeutic use (150) 150
incretins - therapeutic use (149) 149
diabetes mellitus, type 2 - physiopathology (137) 137
glycosylated hemoglobin (136) 136
health aspects (135) 135
insulin resistance (134) 134
studies (132) 132
metformin - adverse effects (129) 129
aged, 80 and over (127) 127
administration, oral (126) 126
young adult (124) 124
diabetes mellitus, type 2 - diagnosis (122) 122
pyrazines - adverse effects (122) 122
triazoles - adverse effects (121) 121
dipeptidyl peptidase-4 inhibitor (120) 120
glycated hemoglobin a - analysis (120) 120
saxagliptin (120) 120
insulin - therapeutic use (119) 119
metformin - administration & dosage (119) 119
thiazolidinediones - therapeutic use (118) 118
cardiovascular disease (117) 117
dose-response relationship, drug (117) 117
patients (117) 117
biomarkers - blood (116) 116
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2037) 2037
French (19) 19
German (16) 16
Spanish (15) 15
Japanese (11) 11
Russian (4) 4
Hungarian (3) 3
Chinese (2) 2
Czech (2) 2
Portuguese (2) 2
Danish (1) 1
Dutch (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes care, ISSN 1935-5548, 08/2018, Volume 41, Issue 8, pp. 1543 - 1556
.... Among the newer generation of glucose-lowering drug classes, sodium-glucose cotransporter 2 inhibitors (SGLT2is... 
Humans | Insulin/administration & dosage | Treatment Outcome | Dipeptidyl-Peptidase IV Inhibitors/administration & dosage | Sodium-Glucose Transporter 2/antagonists & inhibitors | Hypoglycemic Agents/administration & dosage | Signal Transduction/drug effects | Metformin/administration & dosage | Animals | Diabetes Mellitus, Type 2/drug therapy | Blood Glucose/drug effects | Thiazolidinediones/administration & dosage | Sulfonylurea Compounds/administration & dosage | Drug Therapy, Combination | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Insulin - administration & dosage | Sodium-Glucose Transporter 2 Inhibitors | Sulfonylurea Compounds - adverse effects | Thiazolidinediones - administration & dosage | Thiazolidinediones - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Metformin - adverse effects | Blood Glucose - drug effects | Hypoglycemic Agents - administration & dosage | Signal Transduction - drug effects | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Type 2 diabetes | Usage | Analysis | Practice guidelines (Medicine) | Hypoglycemic agents | Dosage and administration | Drug therapy, Combination | Drug therapy | Risk factors | Health care | Physiological effects | Peptides | Glucagon | Entrances | Glycemic index | Disease management | Glucose | Synergism | Guidelines | Cost-benefit analysis | Hyperglycemia | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Excretion | Peptidase | Diabetes mellitus | Health risks | Pharmacology | Insulin | Patients | Mode of action | Inhibitors | Sodium | Sulfonylurea | Diabetes | Metformin | Index Medicus
Journal Article
Current drug targets, ISSN 1389-4501, 2009, Volume 10, Issue 1, pp. 71 - 87
.... Various classes of structurally different DPP IV inhibitors are currently being explored and few of them such as Sitagliptin and Vildagliptin were successfully launched... 
T2DM | GLP-1 | Developmental progress | Alogliptin | Sitagliptin | Selectivity | Vildagliptin | DPP IV | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Drugs, Investigational - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Pyrazines - administration & dosage | Drugs, Investigational - therapeutic use | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Substrate Specificity | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Nitriles - administration & dosage | Dipeptidyl Peptidase 4 - adverse effects | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Diabetes Mellitus, Type 2 - enzymology | Treatment Outcome | Clinical Trials as Topic | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Animals | Pyrazines - adverse effects | Drugs, Investigational - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Nitriles - therapeutic use
Journal Article
Postgraduate medicine, ISSN 0032-5481, 05/2013, Volume 125, Issue 3, pp. 7 - 20
... and glucagon-like peptide-1-independent effects. As a matter of fact, DPP-4 inhibitors improve several cardiovascular risk factors... 
type 2 diabetes mellitus | dipeptidyl peptidase-4 inhibitor | cardiovascular outcomes | gliptin | glucagon-like peptide-1 | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Triazoles - adverse effects | Nitriles - pharmacology | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Body Weight - drug effects | Pyrrolidines - adverse effects | Pyrazines - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Lipids - blood | Adamantane - therapeutic use | Blood Pressure - drug effects | Sitagliptin Phosphate | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Adamantane - pharmacology | Coronary Artery Disease - chemically induced | Risk Factors | Cardiovascular System - drug effects | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Triazoles - pharmacology | Pyrazines - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Pyrazines - pharmacology | Hypoglycemic Agents - adverse effects | Nitriles - therapeutic use | Type 2 diabetes | Prevention | Care and treatment | Safety and security measures | Enzyme inhibitors | Patient outcomes | Reports | Hypoglycemic agents | Dosage and administration | Research | Cardiovascular diseases | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Diabetic medicine, ISSN 0742-3071, 04/2016, Volume 33, Issue 4, pp. 471 - 477
.... Mealtime insulin aspart was used in some regimens. This analysis used the serious adverse events records, which documented the use of ambulance/emergency teams, a hospital/emergency room visit ≤ 24... 
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Insulin Detemir - therapeutic use | Insulin Detemir - economics | Clinical Trials, Phase III as Topic | Hypoglycemic Agents - administration & dosage | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Costs and Cost Analysis | Administration, Oral | Drug Therapy, Combination - economics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Insulin Aspart - economics | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Diabetes Mellitus, Type 1 - economics | Diabetes Mellitus, Type 1 - blood | Insulin, Long-Acting - therapeutic use | Hypoglycemic Agents - adverse effects | Insulin Aspart - adverse effects | Cohort Studies | Insulin Aspart - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diabetes Mellitus, Type 2 - economics | Insulin, Long-Acting - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Insulin Aspart - administration & dosage | Insulin Detemir - administration & dosage | Insulin Detemir - adverse effects | Hypoglycemia - physiopathology | Adult | Hypoglycemia - economics | Hypoglycemia - chemically induced | Severity of Illness Index | Insulin Glargine - adverse effects | Drug Administration Schedule | Insulin Glargine - economics | Insulin Glargine - therapeutic use | Sitagliptin Phosphate - economics | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Health Care Costs | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Combinations | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Adults | Type 1 diabetes | Insulin | Analysis | Emergency medical care | Diabetes | Hypoglycemia | Index Medicus | Complications | Research
Journal Article
Diabetes, obesity & metabolism, ISSN 1463-1326, 09/2017, Volume 20, Issue 2, pp. 344 - 351
...) inhibitors with regard to risk associations with major adverse cardiovascular (CV) events (MACE; non‐fatal myocardial infarction, non... 
cardiovascular disease | DPP‐4 inhibitor | type 2 diabetes | diabetes complications | hypoglycaemia | dapagliflozin | DPP-4 inhibitor | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Diabetic Cardiomyopathies - ethnology | Cardiovascular Diseases - ethnology | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Risk | Diabetes Mellitus, Type 2 - metabolism | Incidence | Hypoglycemia - prevention & control | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - ethnology | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Female | Glucosides - therapeutic use | Diabetic Angiopathies - prevention & control | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 - metabolism | Kaplan-Meier Estimate | Proportional Hazards Models | Diabetic Angiopathies - ethnology | Sweden - epidemiology | Diabetic Cardiomyopathies - epidemiology | Norway - epidemiology | Denmark - epidemiology | Membrane Transport Modulators - therapeutic use | Diabetic Angiopathies - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Type 2 diabetes | Heart | Complications and side effects | Comorbidity | Atrial fibrillation | Glucose | Comparative analysis | Risk factors | Heart attack | Dextrose | Diabetes therapy | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Heart attacks | Peptidase | Mortality | Diabetes mellitus | Hypoglycemia | Patients | Fibrillation | Sodium | Diabetes | Cardiovascular diseases | Health risk assessment | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Original
Journal Article
Clinical therapeutics, ISSN 0149-2918, 01/2013, Volume 35, Issue 1, pp. A33 - A42
Abstract Background Empagliflozin is an oral, potent, and selective inhibitor of sodium glucose cotransporter 2, inhibition of which reduces renal glucose reabsorption and results in increased urinary glucose excretion... 
Internal Medicine | Medical Education | empagliflozin | linagliptin | drug–drug interaction | diabetes | SGLT2 inhibitor | DPP-4 inhibitor | drug-drug interaction | SGLT2 inhibi-tor | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Glucosides - blood | Benzhydryl Compounds - administration & dosage | Area Under Curve | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Humans | Middle Aged | Dipeptidyl Peptidase 4 - blood | Half-Life | Quinazolines - pharmacokinetics | Male | Metabolic Clearance Rate | Glucosides - pharmacokinetics | Purines - administration & dosage | Benzhydryl Compounds - blood | Young Adult | Hypoglycemic Agents - blood | Kidney - metabolism | Benzhydryl Compounds - adverse effects | Drug Interactions | Hypoglycemic Agents - administration & dosage | Purines - blood | Adult | Quinazolines - administration & dosage | Linagliptin | Purines - adverse effects | Drug Therapy, Combination | Benzhydryl Compounds - pharmacokinetics | Glucosides - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - blood | Hypoglycemic Agents - pharmacokinetics | Kidney - drug effects | Drug Administration Schedule | Administration, Oral | Sodium-Glucose Transporter 2 - metabolism | Purines - pharmacokinetics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Quinazolines - blood | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Cross-Over Studies | Analysis of Variance | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Glucosides - administration & dosage | Models, Biological | Quinazolines - adverse effects | Glucose - metabolism | Hypoglycemic Agents - adverse effects | Germany | Type 2 diabetes | Glucose | Drug interactions | Dextrose | Studies | Confidence intervals | Clinical trials | Substance abuse treatment | Diabetes | Drug dosages | Index Medicus
Journal Article